

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Breakthrough innovation & insight

Brii Biosciences Limited

騰盛博藥生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2137)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2024

Reference is made to the annual report of Brii Biosciences Limited (the “**Company**”) for the year ended December 31, 2024 published on April 25, 2025 (the “**2024 Annual Report**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the 2024 Annual Report.

In addition to the disclosures under the section headed “Change in Use of Proceeds from the Global Offering” in the Report of Directors as set out in the 2024 Annual Report, the Company would like to provide the following additional information (additions are shown in underline) in relation to the use of Net Proceeds from the Global Offering pursuant to paragraph 11A of Appendix D2 to the Listing Rules, in particular, with respect to the amount of unutilized use of Net Proceeds as at December 31, 2023, which was brought forward to January 1, 2024:

Original use of proceeds as disclosed in the Announcement	Original allocation of Net Proceeds as disclosed in the Announcement (HK\$ million)	Original percentage of total Net Proceeds as disclosed in the Announcement	Amount of unutilized Net Proceeds as at December 31, 2023 (HK\$ million)	Amount of unutilized Net Proceeds during the Reporting Period (HK\$ million)	Amount of Unutilized Net Proceeds as at December 31, 2024 (HK\$ million)	Amount of utilized Net Proceeds as at December 31, 2024 (HK\$ million)	Changed use of proceeds	Revised allocation of Net Proceeds (HK\$ million)	Revised percentage of total Net Proceeds	Revised amount of Unutilized Net Proceeds as at December 31, 2024 (HK\$ million)
1. Used for our HBV functional cure programs	994.1	38%	494.8	182.5	312.3	681.8	1. Same as original	1,466.6	56%	784.8
1.1 To fund ongoing and planned clinical trials and preparation for regulatory filings for developing combination regimens containing BRII-179, BRII-835 or BRII-877	837.3	32%	338.0	182.5	155.5	681.8	1.1 Same as original	1,195.9	46%	514.1
1.2 Used for regulatory milestone payments for BRII-179	26.1	1%	26.1	-	26.1	-	1.2 Used for IP related payments for BRII-179	140.0	5%	140.0
1.3 Used for the launch and commercialization of HBV curative treatment regimens	130.7	5%	130.7	-	130.7	-	1.3 Same as original	130.7	5%	130.7
2. Used for our HIV programs, funding the ongoing and planned non-clinical studies, clinical trials and preparation for registration filings for BRII-732 and BRII-753	176.0	7%	29.6	5.3	24.3	151.7	2. Same as original	151.7	6%	-

Original use of proceeds as disclosed in the Announcement	Original allocation of Net Proceeds as disclosed in the Announcement (HK\$ million)	Original percentage of total Net Proceeds as disclosed in the Announcement	Amount of unutilized Net Proceeds as at December 31, 2023 (HK\$ million)	Amount of unutilized Net Proceeds during the Reporting Period (HK\$ million)	Amount of Unutilized Net Proceeds as at December 31, 2024 (HK\$ million)	Amount of utilized Net Proceeds as at December 31, 2024 (HK\$ million)	Changed use of proceeds	Revised allocation of Net Proceeds (HK\$ million)	Revised percentage of total Net Proceeds	Revised amount of Unutilized Net Proceeds as at December 31, 2024 (HK\$ million)
3. Used for our MDR/XDR gram-negative infections programs	294.0	11%	241.1	14.6	226.5	67.5	3. Same as original	67.5	3%	-
3.1 To fund the ongoing and planned clinical trials and preparation for registration filings for BRII-636, BRII-672 and BRII-693	234.5	9%	190.1	14.6	175.5	59.0	3.1 Same as original	59.0	2%	-
3.2 Used for regulatory milestone payments for BRII-636, BRII-672 and BRII-693	59.5	2%	51.0	-	51.0	8.5	3.2 Same as original	8.5	0%	-
4. Used for our CNS programs, funding the ongoing and planned non-clinical studies, clinical trials and preparation for registration filings for BRII-296, BRII-297 and other pre-clinical/clinical candidates	496.3	19%	259.8	38.1	221.7	274.6	4. Same as original	274.6	11%	-
5. Used for discovery and business development activities for pipeline expansion	392.0	15%	318.0	20.5	297.5	94.5	5. Same as original	392.0	15%	297.5
6. Used for working capital and general corporate purposes	261.4	10%	-	-	-	261.4	6. Same as original	261.4	10%	-
Total	2,613.8	100%	1,343.3	261.0	1,082.3	1,531.5		2,613.8	100%	1,082.3

The above additional information does not affect other information contained in the 2024 Annual Report. Save as disclosed above, all other information in the 2024 Annual Report remains unchanged.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, August 27, 2025

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Dr. Ankang Li as executive directors; and Dr. Martin J. Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang as independent non-executive directors.